Green Seaweed Caulerpa racemosa as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research
Marine Drugs · 2024
DOI: 10.3390/md22060272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2024. Verfasst von Vincent Lau und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakart…. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by a grant from Kyung Hee University in 2023, National Research Foundation of Korea (NRF) funded by the Ministry of Education, Korea government (MSIT).
Abstract (Originalsprache)
The marine environment provides a rich source of distinct creatures containing potentially revolutionary bioactive chemicals. One of these organisms is Caulerpa racemosa, a type of green algae known as green seaweed, seagrapes, or green caviar. This organism stands out because it has great promise for use in medicine, especially in the study of cancer. Through the utilization of computational modeling (in silico) and cellular laboratory experiments (in vitro), the chemical components included in the green seaweed C. racemosa were effectively analyzed, uncovering its capability to treat non-small cell lung cancer (NSCLC). The study specifically emphasized blocking SRC, STAT3, PIK3CA, MAPK1, EGFR, and JAK1 using molecular docking and in vitro. These proteins play a crucial role in the EGFR Tyrosine Kinase Inhibitor Resistance pathway in NSCLC. The chemical Caulersin (C2) included in C. racemosa extract (CRE) has been identified as a potent and effective agent in fighting against non-small cell lung cancer (NSCLC), both in silico and in vitro. CRE and C2 showed a level of inhibition similar to that of osimertinib (positive control/NSCLC drug).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia.
- Department of Biological Sciences, State Islamic University of Sunan Kalijaga (UIN Sunan Kalijaga), Yogyakarta 55281, Indonesia.
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Faculty of Medicine, Public Health, and Nursing/Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia.
- Collaboration Research Center for Precision Oncology Based Omics-PKR PrOmics, Yogyakarta 55281, Indonesia.
ORCID-Profile: Vincent Lau, Fahrul Nurkolis, Moon Nyeo Park, Didik Setyo Heriyanto, Nurpudji Astuti Taslim, Trina Ekawati Tallei, Happy Kurnia Permatasari, Bonglee Kim
Förderung
- This research was supported by a grant from Kyung Hee University in 2023
- National Research Foundation of Korea (NRF) funded by the Ministry of Education
- Korea government (MSIT)
- Korea Health Industry Development Institute (KHIDI)
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Lau, V., Nurkolis, F., Park, M. N., Heriyanto, D. S., Taslim, N. A., Tallei, T. E., Permatasari, H. K., Tjandrawinata, R. R., Moon, S., & Kim, B. (2024). Green Seaweed Caulerpa racemosa as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research. Marine Drugs. https://doi.org/10.3390/md22060272
Vancouver
Lau V, Nurkolis F, Park MN, Heriyanto DS, Taslim NA, Tallei TE, et al. Green Seaweed Caulerpa racemosa as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research. Marine Drugs. 2024. doi:10.3390/md22060272
BibTeX
@article{Lau2024,
author = {Lau, Vincent and Nurkolis, Fahrul and Park, Moon Nyeo and Heriyanto, Didik Setyo and Taslim, Nurpudji Astuti and Tallei, Trina Ekawati and Permatasari, Happy Kurnia and Tjandrawinata, Raymond R and Moon, Seungjoon and Kim, Bonglee},
title = {Green Seaweed Caulerpa racemosa as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22060272}
}
EUVIMED